Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
VJHemOnc is pleased to be the official media partner for the International Workshop on NHL (iwNHL) 2021, a high-level discussion forum for research leaders in the field of non-Hodgkin lymphoma (NHL).
Presentations and panel discussions with leading experts are now available to watch below.
iwNHL 2021
The International Workshop on NHL (iwNHL) 2021
06–08 May 2021 | Virtual Meeting
iwNHL 2021
The International Workshop on NHL (iwNHL) 2021
06–08 May 2021 | Virtual Meeting
VJHemOnc is pleased to be the official media partner for the International Workshop on NHL (iwNHL) 2021, a high-level discussion forum for research leaders in the field of non-Hodgkin lymphoma (NHL).
Presentations and panel discussions with leading experts are now available to watch below.
Session 1: T-Cell Lymphoma
EBV-associated lymphoproliferations: pathobiology and spectrum
Elaine Jaffe National Cancer Institute, Bethesda, MD, United States
EBV-associated lymphoproliferations: clinical perspective
Olivier Tournilhac Clermont-Ferrand University Hospital, Clermont-Ferrand, France
Biology & management of BIA-ALCL: introduction to BIA-ALCL
Laurence de Leval Lausanne University Hospital, Lausanne, Switzerland
Biology & management of BIA-ALCL: experience from Australia
Miles Prince Peter MacCallum Cancer Centre, Melbourne, Australia
Biology & management of BIA-ALCL: experience from the USA
Neha Mehta-Shah Washington University in St. Louis, St. Louis, MO, United States
Update and perspectives for epigenetic modifier therapy in PTCLs
Lorenzo Falchi Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Session 1 panel discussion
Session 2: Immunotherapy/Microenvironment
Microenvironment in FL pathogenesis and therapy
Patricia Pérez Galán August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain
CBT in specific lymphoma subtypes
Stephen Ansell Mayo Clinic, Rochester, MN, United States
CARs and the tumour microenvironment
Frederick Locke H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
MIDS in combination
Francisco Hernandez-Ilizaliturri Roswell Park Cancer Institute, Buffalo, NY, United States
Session 2 panel discussion
Session 3: Mantle Cell Lymphoma
Mantle cell lymphoma
Elias Campo Hospital Clinic of the University of Barcelona, Barcelona, Spain
Session 3 panel discussion
Session 4: Novel Therapies Part I
ADCs: polatuzumab vedotin
Laurie Sehn BC Cancer Agency, Prince George, Canada
ADCs: ADCT–301 camidanlumab tesirine
Graham Collins Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
CD20/CD3 bispecific antibodies, how to choose?: mosunetuzumab
Stephen Schuster Perelman School of Medicine, Philadelphia, PA, United States
CD20/CD3 bispecific antibodies, how to choose?: CD20 TCB
Franck Morschhauser Lille University Hospital, Lille, France
CD20/CD3 bispecific antibodies, how to choose?: REGN1979
Rajat Bannerji Rutgers Cancer institute of New Jersey, Newark, NJ, United States
Session 4 panel discussion
Session 5: Novel Therapies Part II
Novel BTK inhibitors, how to choose?: acalabrutinib
Thomas Witzig Mayo Clinic Rochester, Rochester , MN, United States
Novel BTK inhibitors, how to choose?: loxo-305
Chan Yoon Cheah Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia
Novel BTK inhibitors, how to choose?: tirabrutinib
Gilles Salles Memorial Sloan Kettering Cancer Center, New York, NY, United States
Novel BTK inhibitors, how to choose?: ibrutinib combinations
Paolo Ghia Vita-Salute San Raffaele University, Milan, Italy
SINE inhibitors
John Kuruvilla Princess Margaret Cancer Centre, Toronto, Canada
Tafasitamab (MOR208) in DLBCL
Gilles Salles Memorial Sloan Kettering Cancer Center, New York, NY, United States
Session 5 panel discussion
Session 6: T-cell Therapies for Lymphoma
Lisocabtagene maraleucel (liso-cel) in DLBCL
Jeremy Abramson Massachusetts General Hospital Cancer Center, Boston, MA, United States
Axicabtagene ciloleucel (axi-cel) in DLBCL
Sattva Neelapu University of Texas MD Anderson Cancer Center, Houston, TX, United States
Tisagenlecleucel in DLBCL
Stephen Schuster Perelman School of Medicine, Philadelphia, PA, United States
CD30-CAR T-cells
Barbara Savoldo University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
CD5 and/or 7 CAR T-cells
Third party EBV T-cells
Susan Prockop Memorial Sloan Kettering Cancer Center, New York, NY, United States
Session 6 panel discussion
Visit The Lymphoma channel for the latest updates from leading experts
